Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours.

Xinhui ChenNicolas IsambertRafael López-LópezMonica GiovanniniNathalie PognanShruti KapoorMichelle QuinlanBenoit YouXiaoming CuiGholamreza RahmanzadehMorten Mau Sorensen

Published in: British journal of clinical pharmacology (2022)

The data from this study demonstrated that capmatinib is a moderate CYP1A2 inhibitor. Capmatinib administration did not cause any clinically relevant changes in midazolam exposure.

Keyphrases

electronic health record
high intensity
big data
machine learning